Open AccessPrognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
Author(s) -
Hiraoka Atsushi,
Kumada Takashi,
Atsukawa Masanori,
Hirooka Masashi,
Tsuji Kunihiko,
Ishikawa Toru,
Takaguchi Koichi,
Kariyama Kazuya,
Itobayashi Ei,
Tajiri Kazuto,
Shimada Noritomo,
Shibata Hiroshi,
Ochi Hironori,
Tada Toshifumi,
Toyoda Hidenori,
Nouso Kazuhiro,
Tsutsui Akemi,
Nagano Takuya,
Itokawa Norio,
Hayama Korenobu,
Imai Michitaka,
Joko Kouji,
Koizumi Yohei,
Hiasa Yoichi,
Michitaka Kojiro,
Kudo Masatoshi
Publication year - 2019
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.2241
Subject(s) - medicine , hepatocellular carcinoma , lenvatinib , hazard ratio , gastroenterology , proportional hazards model , multivariate analysis , body mass index , adverse effect , oncology , confidence interval , sorafenib
Background/aim We assessed suitable factors indicating newly developed lenvatinib (LEN) treatment for unresectable hepatocellular carcinoma (u‐HCC) by investigating real‐world clinical features of patients. Materials/methods One hundred fifty two u‐HCC patients, who receive LEN treatment from March to December 2018, were enrolled. (Child‐Pugh score [CPS] 5/6/7/8 = 76/61/13/2, modified albumin‐bilirubin grade [mALBI] 1/2a/2b/3 = 53/35/60/4). Clinical features were evaluated retrospectively. Results Overall‐response rate (ORR)/disease control rate (DCR) at 1 month after starting LEN were 38.7%/86.0%, respectively. Estimated median time to progression (TTP) was 7.0 months, while median survival time was not reached within the observation period. CPS (≥7) and past history of tyrosine‐kinase inhibitor (TKI) were not significant prognostic factors. mALBI ≥2b was an only significant prognostic factor (HR 4.632, 95%CI 1.649‐13.02, P = 0.004) in Cox‐hazard multivariate analysis. In patients with Child‐Pugh A, c‐index/Akaike's information criterion (AIC) of prognostic predictive value of mALBI were superior to CPS (0.682/135.6 vs 0.652/138.7), while those of stopping LEN also showed that mALBI was better (0.575/447.3 vs 0.562/447.8). Additional analysis of patients with good mALBI (1/2a) revealed that time to stopping LEN was significantly shorter in those with the adverse event (AE) of appetite loss (any grade) than those without ( P = 0.006) and body mass index (BMI) was also lower in patients with that AE (20.3 ± 3.0 vs 23.6 ± 4.0kg/m 2 , P < 0.001), while patients with a hand‐foot skin reaction (any grade) showed good ORR/DCR (59.1%/86.4%) and longer TTP as compared to patients without ( P = 0.007). Conclusion Good hepatic function (mALBI 1/2a) is the best indication for LEN, while potential appetite loss in association with low BMI should be kept in mind in such cases.